Clinical Trials · NCT04007107
A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 103
- Start date
- Jun 2019
- Locations
- 1 site, Netherlands
- Primary endpoint
- Intensity of Injection Site Pain